Germain Craddock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Germain Craddock has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Blake Campbell
Department of Orthopedic Surgery, Dallas Orthopedic Trauma Institute, Methodist Orthopedic Specialists, 221 W. Colorado Blvd., Pavillion II Suite #933, Dallas, TX, 75208, USA
2 shared publicationsChimdindu Obinero
Department of Orthopaedic Surgery Henry Ford Health Detroit Michigan U.S.A.
2 shared publications- Jared M. Mahylis
Henry Ford Health, Detroit, Michigan, USA
2 shared publications - Stephanie J. Muh
Henry Ford Health, Detroit, Michigan, USA
2 shared publications - Alan Afsari
Department of Orthopedic Trauma, Henry Ford St. John Hospital, Detroit, Michigan
1 shared publication Alexander S. Jurayj
Department of Orthopaedic Surgery Henry Ford Health Detroit Michigan U.S.A.
1 shared publication
Latest Publications
- Open Access
- 8 June 2026
- Published by Wiley in Arthroscopy, Sports Medicine, and Rehabilitation
- Vol. 8 (4) , e70047
Perioperative Intravenous Dexamethasone Improves Pain and Functional Outcomes After Arthroscopic Rotator Cuff Repair
Purpose: To evaluate the effect of perioperative dexamethasone on patient‐reported pain, functional outcomes, and minimal clinically important difference (MCID) achievement following arthroscopic rotator cuff repair. Methods: Patients who underwent rotator cuff repair between 2013 and 2023 were identified and divided into groups. Those who received peri operative dexamethasone were compared with controls. Outcomes included visual analog scale (VAS) pain, patient‐reported outcomes measurement information system (PROMIS) upper extremity, PROMIS pain interference, and MCID. Multivariate logistic and linear regression models adjusted for age, sex, body mass index, diabetes, race/ethnicity, smoking, and preoperative opioid use. Subgroup analyses were performed by tear size. Results: A total of 309 patients was included (187 dexamethasone and 122 control). Dexamethasone administration was associated with improved functional recovery and sustained pain reduction. PROMIS upper extremity and PROMIS pain interference scores favored Dexamethasone at 6 weeks, 3 months, and 6 months (all P < .01). VAS pain was significantly lower at 12 months (1.9 ± 2.9 vs 3.1 ± 3.5, P = .003) and 24 months (1.0 ± 2.5 vs 1.8 ± 3.1, P = .035). Only 37% of patients completed a 2‐year follow‐up, limiting the strength of these long‐term comparisons. In small/medium tears, MCID achievement for VAS was greater at 6 weeks (31% vs 21%, P = .041) and 3 months (34% vs 21%, P = .012). Logistic regression confirmed dexamethasone as an independent predictor of early MCID (OR 1.67, 95% CI 1.02‐2.73, P = .041). Large/massive tears showed transient VAS improvement without MCID benefit. Opioid consumption did not differ between groups (all P > .12). Dexamethasone reduced ondansetron use in large/massive tears at 0‐4 hour (β = −0.34, P = .04) and in small/medium tears at 4‐8 hour (β = −0.19, P = .04), with no differences for other antiemetics. Complication rates were similar (11.2% vs 4.9%, P = .055). Conclusions: Perioperative intravenous dexamethasone is a safe adjunct to arthroscopic rotator cuff repair, supporting early antiemetic benefits, durable pain relief, and selective improvements in patient‐reported outcomes. Benefits appear most pronounced in small/medium tears at early follow‐up and large/massive tears at later stages, suggesting tear size‐specific response. Level of Evidence: Level III, retrospective comparative study.
- 8 June 2026
- Published by Wiley in Arthroscopy, Sports Medicine, and Rehabilitation
- Vol. 8 (4) , e70047
Open AccessPerioperative Intravenous Dexamethasone Improves Pain and Functional Outcomes After Arthroscopic Rotator Cuff Repair
Purpose: To evaluate the effect of perioperative dexamethasone on patient‐reported pain, functional outcomes, and minimal clinically important difference (MCID) achievement following arthroscopic rotator cuff repair. Methods: Patients who underwent rotator cuff repair between 2013 and 2023 were identified and divided into groups. Those who received peri operative dexamethasone were compared with controls. Outcomes included visual analog scale (VAS) pain, patient‐reported outcomes measurement information system (PROMIS) upper extremity, PROMIS pain interference, and MCID. Multivariate logistic and linear regression models adjusted for age, sex, body mass index, diabetes, race/ethnicity, smoking, and preoperative opioid use. Subgroup analyses were performed by tear size. Results: A total of 309 patients was included (187 dexamethasone and 122 control). Dexamethasone administration was associated with improved functional recovery and sustained pain reduction. PROMIS upper extremity and PROMIS pain interference scores favored Dexamethasone at 6 weeks, 3 months, and 6 months (all P < .01). VAS pain was significantly lower at 12 months (1.9 ± 2.9 vs 3.1 ± 3.5, P = .003) and 24 months (1.0 ± 2.5 vs 1.8 ± 3.1, P = .035). Only 37% of patients completed a 2‐year follow‐up, limiting the strength of these long‐term comparisons. In small/medium tears, MCID achievement for VAS was greater at 6 weeks (31% vs 21%, P = .041) and 3 months (34% vs 21%, P = .012). Logistic regression confirmed dexamethasone as an independent predictor of early MCID (OR 1.67, 95% CI 1.02‐2.73, P = .041). Large/massive tears showed transient VAS improvement without MCID benefit. Opioid consumption did not differ between groups (all P > .12). Dexamethasone reduced ondansetron use in large/massive tears at 0‐4 hour (β = −0.34, P = .04) and in small/medium tears at 4‐8 hour (β = −0.19, P = .04), with no differences for other antiemetics. Complication rates were similar (11.2% vs 4.9%, P = .055). Conclusions: Perioperative intravenous dexamethasone is a safe adjunct to arthroscopic rotator cuff repair, supporting early antiemetic benefits, durable pain relief, and selective improvements in patient‐reported outcomes. Benefits appear most pronounced in small/medium tears at early follow‐up and large/massive tears at later stages, suggesting tear size‐specific response. Level of Evidence: Level III, retrospective comparative study.
- 14 May 2026
- Published by SAGE Publications in Shoulder & Elbow
Prognostic value of one-week postoperative pain for early recovery after total shoulder arthroplasty
Introduction: Predicting recovery after total shoulder arthroplasty (TSA) remains challenging. While very early postoperative pain (24–48 h) has been linked to outcomes, this metric is rarely available in routine practice. The one-week visit is more universally captured, yet its prognostic value has not been systematically evaluated. Methods: We retrospectively reviewed patients who underwent anatomic or reverse TSA (2016–2021). At one week, patients were classified as Minor Pain (Visual Analog Scale (VAS) ≤ 3) or Major Pain (VAS ≥ 7); those with intermediate scores (VAS 4–6) were excluded. Outcomes included VAS, Patient-Reported Outcomes Measurement Information System (PROMIS)–Upper Extremity (UE), PROMIS–Pain Interference (PI), PROMIS–Depression (D), and active range of motion at six weeks, three months, six months, one year, and ≥2 years. Minimal clinically important difference (MCID) thresholds identified clinically meaningful improvement. Results: Among 217 patients (162 Minor, 55 Major Pain), higher one-week pain was associated with worse VAS, PROMIS–PI, and PROMIS–UE scores through six months (all p < .05), but differences resolved by one year. MCID analyses revealed faster early gains in Minor Pain patients, while Major Pain patients improved more gradually but continued progressing over time. Conclusion: One-week postoperative pain is associated with early recovery patterns after TSA and may inform counseling, rehabilitation, and early pain management. Level of evidence: Level III, retrospective cohort study.
- 14 May 2026
- Published by SAGE Publications in Shoulder & Elbow
Prognostic value of one-week postoperative pain for early recovery after total shoulder arthroplasty
Introduction: Predicting recovery after total shoulder arthroplasty (TSA) remains challenging. While very early postoperative pain (24–48 h) has been linked to outcomes, this metric is rarely available in routine practice. The one-week visit is more universally captured, yet its prognostic value has not been systematically evaluated. Methods: We retrospectively reviewed patients who underwent anatomic or reverse TSA (2016–2021). At one week, patients were classified as Minor Pain (Visual Analog Scale (VAS) ≤ 3) or Major Pain (VAS ≥ 7); those with intermediate scores (VAS 4–6) were excluded. Outcomes included VAS, Patient-Reported Outcomes Measurement Information System (PROMIS)–Upper Extremity (UE), PROMIS–Pain Interference (PI), PROMIS–Depression (D), and active range of motion at six weeks, three months, six months, one year, and ≥2 years. Minimal clinically important difference (MCID) thresholds identified clinically meaningful improvement. Results: Among 217 patients (162 Minor, 55 Major Pain), higher one-week pain was associated with worse VAS, PROMIS–PI, and PROMIS–UE scores through six months (all p < .05), but differences resolved by one year. MCID analyses revealed faster early gains in Minor Pain patients, while Major Pain patients improved more gradually but continued progressing over time. Conclusion: One-week postoperative pain is associated with early recovery patterns after TSA and may inform counseling, rehabilitation, and early pain management. Level of evidence: Level III, retrospective cohort study.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 10 (4)
Geographic Disparities and Workforce Trends in Orthopaedic Surgery
Background: Geographic access to orthopaedic surgery remains limited in nonmetropolitan regions, where over half of US counties lack an orthopaedic surgeon. Osteopathic physicians (DOs) are nearly twice as likely as allopathic physicians (MDs) to practice in these areas, making them a key component of the rural surgical workforce. However, their representation in orthopaedic training has declined since the ACGME-AOA merger. Methods: This cross-sectional national study used 2022 Area Health Resource Files, National Residency Matching Program Match data (2020-2024), and USDA Rural-Urban Continuum Codes (RUCC) to evaluate workforce distribution and match outcomes. Statistical analysis included chi-square testing and odds ratios to assess nonmetropolitan representation by degree and state. Results: Of 30,243 orthopaedic surgeons, 92.9% practiced in metropolitan counties and 7.1% in nonmetropolitan areas. Among DOs, 12.5% practiced in nonmetropolitan regions compared with 6.9% of MDs (OR = 1.92; 95% CI: 1.67-2.19). Eleven states showed significantly higher odds of DOs practicing in nonmetropolitan counties, 9 of these states with longstanding in-state osteopathic schools. From 2010 to 2022, DO presence in nonmetropolitan areas increased by 59%, nearly double the rate of MDs. Despite these contributions, DO match rates in orthopaedic surgery declined from 63.3% to 45.7% between 2020 and 2024, widening the DO-MD gap. Conclusions: DOs play an important role in orthopaedic coverage, as a percentage of their total, in nonmetropolitan communities. Declining match rates raise concerns about the sustainability of this workforce, particularly in states where DOs help maintain surgical access. Structural reforms in training pathways and residency selection may help preserve geographic workforce diversity. Clinical Relevance: Targeted strategies, such as rural training programs, holistic applicant evaluation, and state-specific recruitment efforts, may strengthen access to musculoskeletal care in underserved regions and support a more equitable orthopaedic workforce.
- 1 October 2025
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 10 (4)
Open AccessGeographic Disparities and Workforce Trends in Orthopaedic Surgery
Background: Geographic access to orthopaedic surgery remains limited in nonmetropolitan regions, where over half of US counties lack an orthopaedic surgeon. Osteopathic physicians (DOs) are nearly twice as likely as allopathic physicians (MDs) to practice in these areas, making them a key component of the rural surgical workforce. However, their representation in orthopaedic training has declined since the ACGME-AOA merger. Methods: This cross-sectional national study used 2022 Area Health Resource Files, National Residency Matching Program Match data (2020-2024), and USDA Rural-Urban Continuum Codes (RUCC) to evaluate workforce distribution and match outcomes. Statistical analysis included chi-square testing and odds ratios to assess nonmetropolitan representation by degree and state. Results: Of 30,243 orthopaedic surgeons, 92.9% practiced in metropolitan counties and 7.1% in nonmetropolitan areas. Among DOs, 12.5% practiced in nonmetropolitan regions compared with 6.9% of MDs (OR = 1.92; 95% CI: 1.67-2.19). Eleven states showed significantly higher odds of DOs practicing in nonmetropolitan counties, 9 of these states with longstanding in-state osteopathic schools. From 2010 to 2022, DO presence in nonmetropolitan areas increased by 59%, nearly double the rate of MDs. Despite these contributions, DO match rates in orthopaedic surgery declined from 63.3% to 45.7% between 2020 and 2024, widening the DO-MD gap. Conclusions: DOs play an important role in orthopaedic coverage, as a percentage of their total, in nonmetropolitan communities. Declining match rates raise concerns about the sustainability of this workforce, particularly in states where DOs help maintain surgical access. Structural reforms in training pathways and residency selection may help preserve geographic workforce diversity. Clinical Relevance: Targeted strategies, such as rural training programs, holistic applicant evaluation, and state-specific recruitment efforts, may strengthen access to musculoskeletal care in underserved regions and support a more equitable orthopaedic workforce.